AstraZeneca vaccine as third dose effective against Omicron: Study
PTI, Jan 13, 2022, 4:00 PM IST
Image for representation
London: The AstraZeneca Vaxzevaria vaccine showed an increased antibody response to the Omicron variant of COVID-19 after a third booster dose, preliminary data released by the Anglo-Swedish biopharma major said on Thursday.
In an ongoing safety and immunogenicity trial of the vaccine, a formulation developed by Oxford University and administered in India as Covishield, it was found that given as a third dose increased the body’s immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
A separate analysis of samples from the trial showed increased antibody response to the Omicron variant. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
The company said it is submitting this additional data to health authorities around the world given the urgent need for third dose boosters.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Traffic noise can increase risk of cardiovascular disease: Study
Nearsightedness is at epidemic levels – and the problem begins in childhood
Study finds genetic basis for link between depression, heart disease
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
MUST WATCH
Latest Additions
Some countries, institutions want weak govt to make easy profits: PM Modi
People can talk anything they want to, I know my game better: Virat Kohli on his strike rate
Sexual harassment, stalking case registered against ex-minister H D Revanna and his son Prajwal
Reservation row: Congress campaign ‘biggest lie’ of the decade, says Kishan Reddy
BJP trying religious polarisation in Nagaon: Congress candidate Pradyut Bordoloi